Qurit Alliance consists of a diverse group op people united by a common goal; a world without ALS. We established our alliance to accelerate a breakthrough for ALS medicine. We brought together people, knowledge, best practices and capital to enable the set-up of a new venture capital fund with 100% focus on ALS drug development. We are a foundation (Stichting) and have the ANBI status in The Netherlands, meaning that we are a registered NGO.
This manifesto sets out the intentions and principles that we started out with, when our goal was to support the set-up of a venture capital fund. The Manifesto continues to guide us. Since the ALS Investment Fund has been established, our activities are limited to fulfilling our role as member of the investment committee. In this role, we aim to safeguard the interest of ALS patients as part of the investment decision process.
We act with determination and urgency, inspired by the courageous ALS patients that founded our alliance.
We believe in the power of shared value. We invest not only to gain financial return, but also to make true meaningful impact: finding a cure for ALS.
We form a unique ecosystem. We all have our own specific experience, skills, resources and motivation that we use to contribute to our common goal.
We bundle our forces and only focus on initiatives that target a therapy against ALS. This will realize a breakthrough.
Our investment strategy is rational. We make financially sound business decisions.
We use state of the art technology, best practices and evidence based outcomes to steer our drug development process.
We respect and empower ALS patients worldwide. We connect them with our scientists and investees to participate in research and drug development trials.
We have an open mind. We stimulate our members to share data and IP and create synergy, with respect to the value that they create individually.
We actively pursue bringing drugs and therapies against ALS to the market, through the discoveries made and IP created within our portfolio.
an entrepreneur within the maritime and oil industry. Last year his company received the gold “gazelle” for fastest growing company in Holland and is nominated for EY entrepreneur 2014.
Robbert Jan Stuit
a managing director of an investment company and entrepreneur in real estate and technology. He has vast experience in building companies in every life cycle stage.
Garmt van Soest
a versatile manager with a strong background in business strategy and technology. He has advised Fortune 500 companies in the United States and Europe since 2000.
The three founders of our alliance are ALS-patients themselves. They have driven the initiative from the start, knowing better then anyone else the urgency of bringing a cure closer to the market.
Amyotrophic Lateral Sclerosis
ALS is a neurodegenerative disease characterised by progressive muscular paralysis. It is a devastating disease that leads to muscle weakness, difficulty in swallowing, talking and eventually paralysis and death. Most people who develop ALS are between the age of 40 and 70, with an average age of 55 at the time of diagnosis. However, there are cases of the disease striking persons in their twenties and thirties. Overall, there is a slight male prevalence (M:F ratio~1.5:1).
Currently there is only one drug therapy approved in ALS, which extends life by 3 months only. However, with increasing scientific knowledge and potential to translate this in ALS therapy, we foresee a revolutionary change in ALS treatment.
Approximately two thirds of patients with typical ALS have a spinal form of the disease (limb onset) and present with symptoms related to muscle weakness and wasting, where the symptoms may start in the upper and lower limbs. Gradually, spasticity may develop, affecting manual dexterity and gait. Patients with bulbar onset ALS usually present difficulties in speech and swallowing. Limb symptoms can occur almost simultaneously with bulbar symptoms and in the vast majority of cases will manifest within 1–2 years. Paralysis is progressive and leads to death, due to respiratory failure, within 2–3 years for bulbar onset cases and 3–5 years for limb onset ALS cases.
Incidence of ALS – an orphan disease
Most of the research on prevalence and incidence numbers of ALS has been performed in Europe. It appears that the diversity of ALS epidemiology is related to the population demographics. Also, ALS is more common among the elderly, thus in light of the global trend of increasing life expectancy the incidence numbers may increase. Other factors that have been considered to be related to the occurrence of ALS are environmental risk factors, geographical differences and genomic epidemiology.
A review of published incidence and prevalence literature in Europe and the US revealed that the median incidence rate in Europe is 2.7/100,000 person years resulting in 15.355 estimated cases. Median prevalence is 5.4/100,000 person years corresponding to 39.863 cases (Chiò, et al., 2013). In the US these numbers are similar as the incidence is 10.131 cases annually and the prevalence is 36,480 cases (Borlongan, et al., 2013). Thus, in the Western world approximately 75,000 patients are currently eligible for new drug therapy.
Given its prevalence, ALS is an orphan or rare disease. From a regulatory perspective rare (or orphan) diseases are defined as those affecting less than 200,000 patients in the US or no more than five out of 10,000 of the general population in the EU. Nowadays, a number of unique clinical, regulatory and commercial challenges are associated with the development of therapies for rare diseases.
Therapy for ALS
There are limited pharmacotherapeutic options for the treatment of ALS; the mainstay of management is symptomatic treatment. ALS patients who receive care at a multidisciplinary clinic may get a better prognosis than patients attending a general neurology clinic. Median survival is up to 7.5 months longer for the patient group treated at a multidisciplinary clinic and up to 2 months more for patients with bulbar dysfunction. Overall, the data suggest that active management enhances survival (Gordon, 2013).
Currently, only one drug therapy has been approved for the treatment of ALS. Riluzole (Rilutek) is a neuroprotective drug that blocks glutamatergic neurotransmission in the central nervous system, thereby preventing apoptosis (programmed cell death) of the motor neuron. The beneficial effects of riluzole in the treatment of ALS are, however, rather modest and this therapy only prolongs life by 3 months.
All other pharmacotherapeutic treatment options, commonly used in the clinical management of ALS, are palliative treatments aiming at reducing signs and symptoms associated with the disease but which, on their own, are not specifically indicated for ALS (e.g. treatment of muscle spasms, pain, insomnia, dysphagia and emotional instability).
In addition, supportive non-pharmacotherapeutic treatments may be required, like mechanical ventilation for the management of respiratory insufficiency. However, none of these therapies prolongs life and they should be considered only as symptom suppression options.
Although many drugs have been tested on ALS patients over the last 20 years, none of them has shown adequate clinical efficacy. Reasons for these failures can be diverse, including insufficient exposure at the site of action (pharmacokinetics), insufficient drug efficacy or non-validated drug targets (pharmacodynamics) or poorly designed proof-of-concept trials. Demonstrating efficacy in ALS patients is difficult as there are no reliable biomarkers predictive of efficacy, the manifestation of the disease across the population is highly variable and efficacy is measured by means of subjective questionnaires.
The board works without compensation. Please find our most recent annual report here.
To contribute to our goal, or for more information about Qurit Alliance, please contact us at: firstname.lastname@example.org.
This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation (GDPR). If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny